Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.

Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating
minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In
the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for
childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the
study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone
marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell
markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel
comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference
polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as
complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002
clinical trial information: NCT00114348